Page 2 - Merck

Merck's Covid pill results raise hopes for developing world

Potentially, the drug could be very cheap to manufacture and available at a low cost in developing nations, benefiting millions of people

Merck says it has first effective antiviral pill against Covid-19 pandemic

Drug cuts hospitalisation, deaths by 50%, shows an analysis of a late-stage trial

Covid: Merck's oral pill shows promise against hospitalisation, death

Merck & Co said Friday that its experimental COVID-19 pill reduced hospitalisations and deaths by half in people recently infected with the coronavirus and that it would soon ask health officials in the US and around the world to authorize its use. If cleared, Merck's drug would be the first pill shown to treat COVID-19, a potentially major advance in efforts to fight the pandemic. All COVID-19 therapies now authorised in the US require an IV or injection. Merck and its partner Ridgeback Biotherapeutics said early results showed patients who received the drug, called molnupiravir, within five days of COVID-19 symptoms had about half the rate of hospitalisation and death as patients who received a dummy pill. The study tracked 775 adults with mild-to-moderate COVID-19 who were considered higher risk for severe disease due to health problems such as obesity, diabetes or heart disease. Among patients taking molnupiravir, 7.3 per cent were either hospitalised or died at the end of 30 .

Merck donates Rs 1.7 crore to IIT Bombay for Covid-19 research

Merck announced a donation of Rs 1.7 crore over two years to the IIT, Bombay to support the development of clinical tests for COVID-19 disease severity assessment

Merck extends 2 million euros support to India for coronavirus relief

Science and technology firm Merck on Tuesday announced a support of 2 million euros (Rs 17.85 crore) for India to help the country fight against Covid-19

American drugmaker Merck to help produce J&J's Covid-19 vaccine: Biden

US President Joe Biden on Tuesday announced a collaboration between Johnson & Johnson, Merck, and the federal government to ramp up COVID-19 vaccine production.This comes days after the Food and Drugs Administration (FDA) announced that it had approved the Janssen COVID-19 Vaccine for emergency use in the US in individuals 18 years of age and older.Delivering his remarks at the White House, Biden announced the partnership: "Two of the largest health care and pharmaceutical companies in the world that are usually competitors are working together on the vaccine.""This type of collaborations between the countries we have seen in World War II. We have also invoked the defence production act to equip Merck facilities to safely manufacture the J & J vaccine," he addedBiden said that because of a stepped-up production process, the United States will have enough novel coronavirus vaccines for every American adult by the end of May."This country will have enough vaccines supply for ..

Merck to help make Johnson & Johnson's Covid-19 vaccine, says report

President Joe Biden is expected to make the announcement on Tuesday, the report said

Merck to buy drug developer Pandion Therapeutics for $1.85 billion

The $60-per-share deal represents about 134% premium to Pandion's closing price on Wednesday

US drugmaker Merck's Kenneth Frazier to step down as CEO in June-end

Frazier, 66, will remain with the drugmaker as executive chairman for a transition period to be determined by the board.

Novartis, Merck, Allergan raise US prices, 445 drugs to cost more in 2020

That is above the average of 404 drug price increases in the first three days of January over the past five years

Wall Street holds steady after S&P hits record; Merck, Pfizer stocks gain

The spread in the yield curve has gainedabout 20 basis points since leaving negative territory, a recession indicator, in early September

Govt approves P&G's proposal for acquisition of up to 77.8% stake in Merck

Out of the 77.80% paid-up equity share capital, 51.80% was held by current promoters and up to 26% by public shareholders: Merck

Merck falls 14% in two days after CCI nod for acquisition by P&G

The stock locked in the lower circuit for the second straight day, down 5% at Rs 3,064 on the BSE.

This stock doubled your money in 2018

Thus far in the calendar year 2018, the stock of this pharmaceutical company has zoomed 107% from Rs 1,289, as compared to 4% rise in the S&P BSE Sensex.

Merck hits record high; stock zooms 18%

The stock hit new high of Rs 2,369, rallied 57% from Rs 1,510 since April 19, after P&G Overseas India makes mandatory open offer to acquire 26% stake in the company at price of Rs 1,500.36 per share.

Merck zooms 19% on open offer by Procter & Gamble Overseas India

The stock surged 19% to Rs 1,795, also its record high on the BSE after the Procter & Gamble Overseas India makes mandatory open offer at price of Rs 1,500.36 per share

Merck expects strong growth from India, says executive board member

The life science division which manufactures laboratory materials, chemicals and is the largest of its segment in India

Merck may sell consumer health business to focus on new drugs

is exploring sale or strategic partnership for its consumer health business including India as it continues focus to develop innovative drugs.The plan to hive off consumer health business is second such move by the drug maker which sold its biosimilar business to Fresenius earlier this year.The German drug maker Merck KGaA operates in 66 countries and its business is spread across pharmaceuticals, laboratory solutions, chemicals and liquid crystals. In 2016 the company had global sales of over 15 billion Euros. Consumer health contributed to 850 million Euros.Merck, which has been present in India for over five decades, operates through five main companies including its listed entity Merck Limited. Merck did not respond to an email query and did not share the most recent consumer health sales figures for India. Merck Ltd 2015 annual report shows the business contributed over Rs 200 crore or around 24 per cent of its Rs 904 crore sales (the company follows January-December ...

Merck opens first India M Lab in Bengaluru to help biopharma firms scale

Lab will also help with technology absorption, making drugs for clinical trials and regulatory nods

Merck hits 52-week high as Q3 profit doubles

The stock rallied 13% to Rs 906 in intra-day after reported profit of Rs 27.54 crore in Q3CY16 against Rs 12.51 crore in the same quarter last year.